She, Dewei

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., et al. (2019) · The Lancet

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 756

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial

Simpson, E. L., Parnes, J. R., She, D., Crouch, S., Rees, W., Mo, M., & van der Merwe, R. (2019) · Journal of the American Academy of Dermatology

Dermatology and Skin DiseasesAsthma and respiratory diseases

Cited by 328

A phase 2 randomized controlled study of tralokinumab in subjects with idiopathic pulmonary fibrosis

Parker, J. M., Glaspole, I. N., Lancaster, L. H., Haddad, T. J., She, D., Roseti, S. L., Fiening, J. P., Grant, E. P., Kell, C. M., & Flaherty, K. R. (2018) · American Journal of Respiratory and Critical Care Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisChronic Obstructive Pulmonary Disease (COPD) Research

Cited by 129